Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Abstract:
Iroko Pharmaceuticals, LLC and Aptuit Inc. announced today that Aptuit will provide manufacturing scale-up services as Iroko progresses its novel pain medications to Phase III clinical trials.

Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Philadelphia, PA and Greenwich, CT | Posted on May 4th, 2011

Under the services agreement, Aptuit will produce for Iroko Phase III supplies of lower dose, nanotechnology formulations for multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Iroko has already completed Phase II studies for all of these products. Aptuit will also make batch material to satisfy requirements for product registrations.

While serving as a contract manufacturer, Aptuit will make use of the proprietary SoluMatrix™ technology of Iroko partner iCeutica Inc (recently acquired by Iroko on April 26, 2011 as announced in a previous press release). This nanoformulation technology makes possible the production of medications consisting of sub-micron, fast-dissolving drug particles.

John Vavricka, Iroko's Chief Executive Officer, commented, "Our strategic focus responds to the directive of the US Food and Drug Administration that NSAIDs should be used at the lowest effective dose for the shortest possible duration.1 We believe our patented nanoformulations will enable the development of NSAIDs at significantly lower doses without compromising onset of action or effectiveness. The consistent quality and attention to detail which Aptuit brings to its work will be an important resource as we advance these products toward the market."

"The confidence Iroko has placed in our ability to support them through this project as they progress their Phase III programs is a testament to the expertise of our team and the rigor of our science," said Timothy Tyson, Executive Chairman and Chief Executive Officer of Aptuit. "We look forward to working closely with Iroko to deliver a complete range of manufacturing services and to serve as a partner in advancing these important products."

####

About Iroko Pharmaceuticals, LLC
Iroko Pharmaceuticals, LLC is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas. Iroko is focused on the maximization of the revenue potential of these products through directed selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient therapies. Iroko currently has several products under development using iCeutica's proprietary SoluMatrix™ Platform.

About Aptuit:
Aptuit Inc. is a global pharmaceutical services company focused on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit’s employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit, please visit www.aptuit.com, or for more information about Aptuit’s acquisition of the Verona Medicines Research Centre operations, please visit www.aptuit.com/Verona.

For more information, please click here

Contacts:
Iroko contact:
Phoenix IP Ventures
Lisa Gray, Managing Partner
267-765-3233

or
Aptuit contact:
Feinstein Kean Healthcare
Krystle Ficco
617-761-6702

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New solar power material converts 90 percent of captured light into heat: SunShot Project aims to make solar cost competitive October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Microrockets fueled by water neutralize chemical and biological warfare agents October 29th, 2014

Nanosafety research – there’s room for improvement October 29th, 2014

Nanomedicine

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Molecular beacons shine light on how cells 'crawl' October 27th, 2014

New nanodevice to improve cancer treatment monitoring October 27th, 2014

Announcements

New solar power material converts 90 percent of captured light into heat: SunShot Project aims to make solar cost competitive October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Microrockets fueled by water neutralize chemical and biological warfare agents October 29th, 2014

Nanosafety research – there’s room for improvement October 29th, 2014

Alliances/Partnerships/Distributorships

'Electronic skin' could improve early breast cancer detection October 29th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014

New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE